Breaking News Instant updates and real-time market news.

BOX

Box

$16.71

0.23 (1.40%)

, HPQ

HP Inc.

$20.07

-0.085 (-0.42%)

18:52
11/26/19
11/26
18:52
11/26/19
18:52

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Box (BOX) up 2.4%... HP Inc (HPQ) up 1.7%... Keysight Technologies (KEYS) up 1.4%... Veeva (VEEV) up 1.1%... VMWare (VMW) up 0.7%. ALSO HIGHER: Tonix Pharma (TNXP) up 9.5% after getting FDA notice for Tonmya as potential PTSD treatment. DOWN AFTER EARNINGS: Central Garden & Pet (CENTA) down 10.7%... Guess (GES) down 4.6%. ALSO LOWER: Aravive (ARAV) down 13.3% after equity offering... Dell Technologies (DELL) down 3.2% after cutting FY20 revenue guidance. Movers as of 18:40ET.

BOX

Box

$16.71

0.23 (1.40%)

HPQ

HP Inc.

$20.07

-0.085 (-0.42%)

KEYS

Keysight Technologies

$105.82

-0.48 (-0.45%)

VEEV

Veeva

$159.25

2.21 (1.41%)

VMW

VMware

$164.90

-3.68 (-2.18%)

TNXP

Tonix Pharmaceuticals

$1.05

-0.2 (-16.00%)

CENTA

Central Garden & Pet Co.

$29.56

-0.38 (-1.27%)

GES

Guess

$19.12

0.67 (3.63%)

ARAV

Aravive

$9.50

-0.06 (-0.63%)

DELL

Dell Technologies

$53.30

-1.755 (-3.19%)

  • 26

    Nov

  • 26

    Nov

  • 26

    Nov

  • 26

    Nov

  • 26

    Nov

  • 26

    Nov

  • 26

    Nov

  • 02

    Dec

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 11

    Dec

  • 12

    Dec

  • 27

    Nov

BOX Box
$16.71

0.23 (1.40%)

10/10/19
BREN
10/10/19
INITIATION
Target $18
BREN
Hold
Box initiated with a Hold rating at Berenberg
Berenberg analyst Brett Knoblauch initiated coverage of Box with a Hold rating and $18 price target.
11/12/19
11/12/19
INITIATION

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CSX (CSX) downgraded to Hold from Buy at Deutsche Bank. 2. Eaton (ETN) downgraded to Hold from Buy at HSBC. 3. Amneal Pharmaceuticals (AMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Christopher Schott saying while some of the challenges facing the company appear fixable, like supply penalties and plant utilization, many appear fundamental, a function of the evolving dynamics in the U.S. generics market. 4. Albemarle (ALB) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan saying with lithium prices falling below historical levels, global lithium suppliers may have to reduce output and wait for demand to catch up. 5. Box (BOX) downgraded to Market Perform from Outperform at JMP Securities with analyst Erik Suppiger citing concerns that after the challenging October quarter, the pipeline of the company's business has slowed. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/19
JMPS
11/12/19
DOWNGRADE
JMPS
Market Perform
Box downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Erik Suppiger downgraded Box to Market Perform from Outperform. The analyst attributes the rating change to concerns that after the challenging October quarter, the pipeline of the company's business has slowed. While his earnings forecasts are moving higher to reflect the company's cost-cutting actions, Suppiger adds that with enterprise value to expected 2021 revenue at a 3.2-times multiple, Box shares are "fairly valued".
11/12/19
JMPS
11/12/19
DOWNGRADE
JMPS
Market Perform
Box downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Erik Suppiger downgraded Box to Market Perform from Outperform.
HPQ HP Inc.
$20.07

-0.085 (-0.42%)

11/18/19
DBAB
11/18/19
NO CHANGE
DBAB
Hold
HP letter to Xerox indicates openness in combination, says Deutsche Bank
Deutsche Bank analyst Jeriel Ong says that while HP Inc.'s (HPQ) offer rejection reduces the odds of Xerox (XRX) being the acquirer, he believes the letter also communicates the openness HP has in evaluating a combination. It is unclear whether Xerox increasing the offer price would improve the odds of a combination as HPQ is already concerned about debt load at the $22 per share offer, Ong tells investors in a research note. The analyst continues to believe that a combination makes sense with HP as the acquirer rather than the target. He keeps a Hold rating on HP.
11/22/19
DBAB
11/22/19
NO CHANGE
DBAB
Hold
HP, Xerox deal 'continues to be in play,' says Deutsche Bank
While admitting there is a bit of a "he said, she said" dynamic playing out, Deutsche Bank analyst Jeriel Ong sees the interaction between HP Inc. (HPQ) and Xerox (XRX) as a "positive indicator that some kind of a deal continues to be in play." The analyst, who says he has no incremental information to discern whether Xerox's claim that HP has not agreed to mutual diligence as a delay tactic holds merit or not, believes that a combined company makes more sense with HP as the acquirer rather than the target.
11/25/19
LOOP
11/25/19
NO CHANGE
Target $47
LOOP
Buy
Xerox price target raised to $47 from $42 at Loop Capital
Loop Capital analyst Ananda Baruah raised his price target on Xerox (XRX) to $47 and kept his Buy rating, saying that regardless of the outcome of its efforts to acquire HP Inc (HPQ), his recent discussion with its management has made him more bullish on the company's prospects. The analyst sees the new management committed to "creativity, sophistication, and velocity for creating both company and equity value", adding that at 9.3-times enterprise value to expected free cash flow, the stock offers "inherent" free cash flow value.
11/25/19
JPMS
11/25/19
NO CHANGE
Target $19
JPMS
Neutral
HP Inc. risks skewed to downside near-term, says JPMorgan
JPMorgan analyst Paul Coster says that while HP Inc.'s (HPQ) "likely frosty" response to what could evolve into a hostile bid from Xerox (XRX) is probably the main focus of investors into the fiscal Q4 results, the stock's near-term risks are skewed to the downside. The print itself is unlikely to strengthen HP's case for independence if continued declines in the high-margin printer segment shift sentiment in favor of "urgent cost-cutting of the kind already instituted by Xerox," Coster tells investors in a research note. He believes a "bad print" could reinforce the view that HP's personal and office printer business is in secular decline, whether or not combined with that of Xerox. Coster keeps an Underweight rating on HP Inc. shares with a $19 price target.
KEYS Keysight Technologies
$105.82

-0.48 (-0.45%)

11/18/19
BOFA
11/18/19
INITIATION
Target $115
BOFA
Keysight Technologies resumed with Neutral at BofA/Merrill
BofA/Merrill analyst David Ridley-Lane resumed coverage of Keysight Technologies with a Neutral rating and $115 price target. The analyst says the stock gives investors exposure to the "increasing power of mobile networks and the new opportunities they enable," while its $650M R&D budget gives the company product differentiation and generates margin expansion. Ridley-Lane adds that his price target models a 23-times forward earnings multiple, which is in line with Keysight's peers.
10/17/19
SUSQ
10/17/19
INITIATION
Target $115
SUSQ
Positive
Keysight Technologies initiated with a Positive at Susquehanna
Susquehanna analyst Mehdi Hosseini initiated coverage of Keysight Technologies with a Positive rating and $115 price target.
09/09/19
DBAB
09/09/19
NO CHANGE
DBAB
Buy
Deutsche analysis suggests 40% upside potential in Keysight Technologies
Deutsche Bank analyst Brian Yun says his sum-of-the-parts analysis suggests 40%-plus upside potential in shares of Keysight Technologies. The analyst sees a pathway to $140 levels for the stock via a sum-of-the-parts valuation. Software is a "meaningful differentiator" for the company versus other test and measurement peers, Yun tells investors in a research note. He highlights the "depth" of Keysight's software portfolio, design wins, and industry partnerships. Further, software should accelerate the company's sales growth and margin expansion ahead of consensus and buy-side expectations, warranting a higher multiple for the stock, says Yun.
10/17/19
SUSQ
10/17/19
INITIATION
Target $115
SUSQ
Positive
Susquehanna starts Keysight Technologies with Positive, $115 price target
Susquehanna analyst Mehdi Hosseini initiated coverage of Keysight Technologies with a Positive rating and $115 price target. 5G is the key multi-year secular growth driver, and Keysight offers a broad range of equipment to materialize growth from the different stages of 5G, Hosseini tells investors in a research note. The analyst believes the rollout of 5G worldwide comes with "significant opportunity for the company."
VEEV Veeva
$159.25

2.21 (1.41%)

10/03/19
WBLR
10/03/19
NO CHANGE
WBLR
Outperform
Veeva introduced 'bullish' 2025 sales target of $3B, says William Blair
William Blair analyst Bhavan Suri says Veeva Systems management yesterday introduced "bullish" long-term targets, including a $3B revenue run-rate goal by calendar 2025, indicating 19% annual growth, largely reflective of growth within life sciences offerings. Increased "agility and speed to market capabilities," as well as the continued adoption of Veeva's early stage products, will lead to "multiple years" of greater than 20% revenue growth with "best-in-class" operating margins in excess of 35%, Suri tells investors in a research note. He reiterates an Outperform rating on the shares.
10/03/19
SPHN
10/03/19
NO CHANGE
Target $185
SPHN
Overweight
Veeva leaving room for investments or M&A with 2025 targets, says Stephens
Stephens analyst James Rutherford said some investors may have expected a more aggressive margin outlook than the five-year 35%+ adjusted EBIT margins guidance that Veeva announced yesterday at its investor day, but he believes the company is leaving itself room to make incremental investments and/or pursue additional strategic M&A that could help it achieve its $3B annual revenue target more quickly. Rutherford, who continues to see Veeva as one of the best positioned companies in its industry, keeps an Overweight rating and $185 price target on the shares.
09/26/19
RAJA
09/26/19
UPGRADE
Target $180
RAJA
Outperform
Veeva pullback offers 'attractive' entry point, says Raymond James
Raymond James analyst Brian Peterson upgraded Veeva Systems to Outperform from Market Perform with a $180 price target ahead of the company's analyst day next week. The recent pullback provides an attractive entry point into the shares, Peterson tells investors in a research note. Specifically, Peterson says he expects management to provide incremental detail on key growth areas including EDC and efforts outside of life sciences, which could be reaching an inflection point, and says that with each of these emerging growth opportunities equating to a $1B+ TAM, this should give investors increasing confidence in the durability of Veeva's growth profile.
10/03/19
GUGG
10/03/19
NO CHANGE
GUGG
Buy
Veeva right to invest, but first reaction likely negative, says Guggenheim
After Veeva CFO Tim Cabral announced a new long-term goal of 19% revenue CAGR through 2025 to $3B and a 2025 target for 35%+ EBIT margins at the company's investor day meeting, Guggenheim analyst Ken Wong said he expects the initial investor reaction to the new 5-year targets to be mildly negative and for skeptics to "zero in" on the margins target being seen as a step down from the 38% levels projected for FY20. However, Wong said the growth targets are better than he expected, thinks the margins view feels "conservative" and expects any negativity to be short lived. The analyst, who views the company's elevated investments as appropriate given Veeva's product roadmap, keeps a Buy rating on the stock.
VMW VMware
$164.90

-3.68 (-2.18%)

11/21/19
NOMU
11/21/19
INITIATION
Target $60
NOMU
Neutral
Nomura starts Dell at Neutral, says 'not compelling' without VMware
Nomura Instinet analyst Jeffrey Kvaal initiated coverage of Dell Technologies (DELL) with a Neutral rating and $60 price target. The analyst believes "classic Dell has positives that may fade," threatened by public cloud growth, and notes that Dell is exposed to a softening macro climate. As such, investors may choose to invest in VMware's (VMW) growth directly, Kvaal tells investors in a research note. The analyst says Dell is "not compelling" without VMware.
11/04/19
PIPR
11/04/19
INITIATION
Target $29
PIPR
Neutral
Nutanix assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst James Fish assumed coverage of Nutanix (NTNX) with a Neutral rating and $29 price target. Competition, particularly from VMware (VMW), is a "major concern," Fish tells investors in a research note. Further, Nutanix's current model of spending more incremental dollars on sales and marketing than the incremental billings/revenue is not sustainable, and does not properly balance growth and margin, says the analyst. He would become more constructive on the shares with a return to "consistent execution."
10/16/19
MSCO
10/16/19
NO CHANGE
MSCO
Morgan Stanley trims targets for 'high multiple' software stocks amid pullback
Morgan Stanley analyst Keith Weiss, Stan Zlotsky and others in the firm's Software team noted that software stocks have pulled back 23% on average from their 52-week highs, which they attribute to a combination of high growth software multiples being at historical peaks, a volatile macro environment and sector rotations away from momentum names. Though they think the pullback raises the question of whether it is time to start buying software again, the analysts note that high growth multiples are still well above historical averages and the firm's Q3 CIO survey is suggesting a steep deceleration in software spending growth into 2020. Given those facts, as well as difficult second half comps for numerous companies in the space, they see unfavorable risk/rewards for "a lot of the high fliers," the analysts said. The team has lowered their price targets for Liveramp (RAMP) to $58 from $64, for Workiva (WK) to $42 from $46, for PagerDuty (PD) to $34 from $43, for MongoDB (MDB) to $150 from $160, for Yext (YEXT) to $15 from $16 and for VMware (VMW) to $170 from $188.
10/11/19
OPCO
10/11/19
NO CHANGE
OPCO
Oppenheimer lowers price targets for MongoDB, Twilio, New Relic ahead of reports
Oppenheimer analyst Ittai Kidron said he expects solid results from the Analytics, Collaboration, and Infrastructure software group, though upside may be more constrained given several vendors face tougher year-over year comparisons and it seems investors have become more sensitive to high valuations. While he said MongoDB (MDB), Twilio (TWLO), Smartsheet (SMAR) and Elastic (ESTC) remain top picks, he sees lower near-term upside given tough comps in the second half and sees them as better positioned to deliver bigger upside in calendar 2020, Kidron tells investors in his group preview. Ahead of results from the group, Kidron lowered his price target for MongoDB to $155 from $180, for Twilio to $145 from $160 and for New Relic (NEWR) to $80 from $85. He also noted that he is bullish on Alteryx (AYX), Atlassian (TEAM) and VMware (VMW).
TNXP Tonix Pharmaceuticals
$1.05

-0.2 (-16.00%)

08/30/19
ROTH
08/30/19
NO CHANGE
Target $1.3
ROTH
Buy
Tonix Pharmaceuticals price target lowered to $1.30 from $4 at Roth Capital
Roth Capital analyst Scott Henry lowered his price target for Tonix Pharmaceuticals to $1.30 from $4.00 while maintaining a Buy rating on the shares. While dilution from the company's equity offering in July was "painful," it should have enough cash runway into a data release, Henry tells investors in a research note.
04/18/19
04/18/19
UPGRADE
Target $4

Buy
Tonix Pharmaceuticals upgraded to Buy at Roth Capital
As previously reported, Roth Capital analyst Scott Henry upgraded Tonix Pharmaceuticals to Buy from Neutral given that the company is attempting its third shot at the PTSD indication with the RECOVERY trial, enrollment adjustments give the trial a "reasonable shot at success," the cash runway could get the company to the key PTSD data readout in the first half of 2020, and the stock looks interesting using only a about 20% chance at approval. The analyst also raised his price target on the shares to $4 from 75c.
04/18/19
ROTH
04/18/19
UPGRADE
ROTH
Buy
Tonix Pharmaceuticals upgraded to Buy from Neutral at Roth Capital
CENTA Central Garden & Pet Co.
$29.56

-0.38 (-1.27%)

11/28/18
BMOC
11/28/18
NO CHANGE
Target $42
BMOC
Outperform
Central Garden & Pet Co. price target lowered to $42 from $45 at BMO Capital
BMO Capital analyst Shannon Coyne lowered her price target on Central Garden & Pet Co to $42 after its Q4 results, saying its "strong expense control and a lower-than-expected tax rate offset a slightly disappointing top line". The analyst sees some near term headwinds for the stock around commodity, freight, and labor costs as well as uncertainty on tariffs, but keeps her Outperform rating longer term based on the management's "strong focus on cost reduction".
GES Guess
$19.12

0.67 (3.63%)

11/26/19
JEFF
11/26/19
NO CHANGE
Target $38
JEFF
Buy
Zumiez price target raised to $38 from $34 at Jefferies
Jefferies analyst Janine Stichter said she finds that many of the larger retro and streetwear brands are seeing search interest track flat to down with weakened social media engagement, which she views as a signal that the the cycle is now past peak, although the category is still broadly healthy. Even with a fairly heavy reliance on Vans, Zumiez (ZUMZ) is sufficiently diverse to weather a deceleration in the retro cycle and data also suggests a major resurgence in skateboards, which is positive for Zumiez, said Stichter, who raised her price target on the stock to $38 from $34 and keeps a Buy rating on the shares. Despite the broader downtrend in the retro brand cycle, he checks also indicate that the Guess (GES) brand is "in the earlier stages of capitalizing on its status as a retro 90s brand," added Stichter.
03/21/19
JEFF
03/21/19
NO CHANGE
Target $24
JEFF
Buy
Guess in penalty box but fundamentals healthy, says Jefferies
While Guess shares will be in the penalty box near-term as an inventory overhang weighs on margins, its fundamentals remain healthy, Jefferies analyst Janine Stichter tells investors in a research note. The analyst expects CEO Carlos Alberini's return to be a positive catalyst for Guess and that his first earnings call as CEO was a strong one. Significant market share potential remains in Europe and Asia for Guess while North America appears to be gaining momentum, says Stichter. She keeps a Buy rating on the shares with a $24 price target.
06/27/19
JEFF
06/27/19
NO CHANGE
JEFF
Jefferies reiterates Buys on Guess, American Eagle after female survey
After surveying 600 female consumers to analyze changes in brand momentum, Jefferies analyst Janine Stichter reiterates Buy ratings on both Guess (GES) and American Eagle (AEO). Results are favorable for Guess, which is seeing an increase in brand awareness and improved purchasing intent, Stichter tells investors in a research note. For American Eagle, investments in the store experience are translating into improved customer satisfaction, while Aerie also continues to score well across all key metrics, adds the analyst.
07/22/19
JEFF
07/22/19
NO CHANGE
Target $24
JEFF
Buy
Guess near-term results may be better than what's priced in, says Jefferies
Geolocation data suggest "significant" improvement in June traffic levels for Guess, Jefferies analyst Janine Stichter tells investors in a research note. Further, web traffic data show rising penetration of Guess's shopping cart and checkout page, suggesting improving conversion, adds the analyst. As a result, she believes the company's near-term performance may not be as challenging as the market is pricing in. In addition, Guess's longer term opportunity "remains very much intact," says Stichter. The analyst keeps a Buy rating on the shares with a $24 price target.
ARAV Aravive
$9.50

-0.06 (-0.63%)

11/20/19
HCWC
11/20/19
NO CHANGE
Target $31
HCWC
Buy
Aravive price target raised to $31 from $18 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Aravive to $31 from $18 and reiterated a Buy rating after the company updated positive data from platinum-resistant ovarian cancer patients receiving AVB-500 plus chemotherapy in an ongoing Phase 1b study, saying results from 31 patients treated with the 10mg/kg dose of AVB-500 in combination with pegylated liposomal doxorubicin or with paclitaxel support and extend the prior observation of efficacy in 28 patients. In a research note to investors, Pantginis says the current results point to positive outcomes at higher doses, and that data on ORR and PFS in these patients are expected in mid-2020.
11/20/19
PIPR
11/20/19
NO CHANGE
Target $36
PIPR
Overweight
Aravive price target raised to $36 from $15 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Aravive to $36 from $15 after the company updated data from 31 platinum-resistant ovarian cancer patients receiving AVB-500 plus chemotherapy in an ongoing Phase Ib study. The stock in morning trading is up 72%, or $4.80, to $11.50. Seventeen of 31 patients achieved the minimal efficacious concentration of AVB-500, which significantly correlated to a four-fold increase in progression free survival, Tenthoff tells investors in a research note. High AVB-500 exposure also resulted in an overall response rate of 29% versus 14% for low exposure, adds the analyst. He points out the results exceed the historical three-to-four month median progress free survival and 10%-15% response in this population. Citing the "positive" Phase Ib data, Tenthoff reiterates an Overweight rating on Aravive.
10/10/19
HCWC
10/10/19
INITIATION
Target $18
HCWC
Buy
Aravive initiated with a Buy rating at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis initiated coverage of Aravive with a Buy rating and $18 price target, stating that he thinks the company's lead asset, AVB-500, could be "compelling" for the treatment of various tumor indications and "a valuable ally in the context of combinatory therapies in multiple lines of treatment." He also thinks the safety and efficacy data reported from its ongoing Phase 1b/2 study opens the possibility of exploring an accelerated path forward with the FDA.
11/20/19
WEDB
11/20/19
NO CHANGE
Target $28
WEDB
Outperform
Aravive price target raised to $28 from $12 at Wedbush
Wedbush analyst David Nierengarten reiterated an Outperform rating on Aravive and raised his price target on the shares to $28 from $12 following the reporting of "encouraging" AVB-500 dose-escalation data from the Phase 1b/2 trial evaluating the decoy AXL receptor in combination with standard single-agent chemo in 31 pts with platinum-resistant ovarian cancer. Nierengarten said he believes AVB-500's emerging clinical profile in platinum-resistant ovarian cancer and "encouraging" exposure-response relationship continues to support his view of its best-in-class status among AXL pathway inhibitors. As such, the analyst said he would be a buyer of Aravive shares ahead of the preliminary readout from the higher 15 and 20 mg/kg dose groups, which he expects will be positive, that's anticipated in the middle of next year.
DELL Dell Technologies
$53.30

-1.755 (-3.19%)

11/21/19
11/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Noble Energy (NBL) initiated with a Buy at MKM Partners. 2. Smith & Nephew (SNN) initiated with a Buy at Citi. 3. Dell Technologies (DELL) initiated with a Neutral at Nomura Instinet. 4. Virgin Galactic (SPCE) initiated with an Outperform at Credit Suisse. 5. Alector (ALEC) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/19
FBCO
08/30/19
NO CHANGE
FBCO
Dell Technologies price target raised to $61 from $58 at Credit Suisse
Credit Suisse analyst Matthew Cabral maintained a Neutral rating on Dell Technologies, but raised his price target on shares to $61 from $58 following the company's "better-than-expected" Q2 earnings results. Despite the sizeable EPS beat, the analyst is concerned by management commentary indicating a "more aggressive pricing environment" in he second half of the year, especially considering margins have been a key offset for Dell and the wider industry.
11/21/19
NOMU
11/21/19
INITIATION
Target $60
NOMU
Neutral
Dell Technologies initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal initiated coverage of Dell Technologies with a Neutral rating and $60 price target.

TODAY'S FREE FLY STORIES

UBER

Uber

$28.60

-0.08 (-0.28%)

11:10
12/13/19
12/13
11:10
12/13/19
11:10
Periodicals
Uber submits appeal to restore taxi license in London, Reuters reports »

Uber has submitted an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

SNAP

Snap

$14.78

0.33 (2.28%)

, REGN

Regeneron

$376.32

4.22 (1.13%)

11:08
12/13/19
12/13
11:08
12/13/19
11:08
On The Fly
Snap upgrade, Sarepta target raises among today's top analyst actions »

Check out today's top…

SNAP

Snap

$14.78

0.33 (2.28%)

REGN

Regeneron

$376.32

4.22 (1.13%)

OIS

Oil States

$16.67

-0.965 (-5.47%)

PTEN

Patterson-UTI

$10.05

-0.33 (-3.18%)

SRPT

Sarepta

$133.84

33.45 (33.32%)

GILD

Gilead

$66.05

-1.59 (-2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 23

    Mar

NUE

Nucor

$57.08

-1.03 (-1.77%)

11:05
12/13/19
12/13
11:05
12/13/19
11:05
Hot Stocks
Nucor raises quarterly cash dividend to 40.25c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.40

0.13 (2.47%)

11:05
12/13/19
12/13
11:05
12/13/19
11:05
Options
Aphria call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
12/13/19
12/13
11:00
12/13/19
11:00
General news
Today's U.S. reports »

Today's U.S. reports…

GPS

Gap

$16.66

-0.36 (-2.12%)

10:55
12/13/19
12/13
10:55
12/13/19
10:55
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
12/13/19
12/13
10:55
12/13/19
10:55
Conference/Events
Federal Reserve Bank of New York president participates in a discussion »

New York Federal Reserve…

SPT

Sprout Social

$0.00

(0.00%)

10:52
12/13/19
12/13
10:52
12/13/19
10:52
Syndicate
Sprout Social indicated to open at $19.25, IPO priced at $17.00 »

Sprout Social (SPT)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$317.49

0.35 (0.11%)

10:47
12/13/19
12/13
10:47
12/13/19
10:47
General news
U.S. Trade Representative says Phase One trade deal with China 'enforceable' »

United States Trade…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$317.49

0.35 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$286.83

3.03 (1.07%)

10:45
12/13/19
12/13
10:45
12/13/19
10:45
Options
UnitedHealth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/13/19
12/13
10:45
12/13/19
10:45
General news
Breaking General news story  »

New York Federal Reserve…

10:45
12/13/19
12/13
10:45
12/13/19
10:45
General news
Breaking General news story  »

New York Federal Reserve…

ALG

Alamo Group

$117.70

0.51 (0.44%)

10:43
12/13/19
12/13
10:43
12/13/19
10:43
Conference/Events
Alamo Group management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

ABT

Abbott

$86.48

0.5 (0.58%)

10:40
12/13/19
12/13
10:40
12/13/19
10:40
Hot Stocks
Abbott raises quarterly dividend 12.5% to 36c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPO

Exponent

$65.46

-0.62 (-0.94%)

10:37
12/13/19
12/13
10:37
12/13/19
10:37
Conference/Events
Exponent management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FLWS

1-800-Flowers.com

$13.56

0.29 (2.19%)

10:35
12/13/19
12/13
10:35
12/13/19
10:35
Conference/Events
1-800-Flowers.com management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FFIV

F5 Networks

$142.79

-0.84 (-0.58%)

10:35
12/13/19
12/13
10:35
12/13/19
10:35
Periodicals
Police raid Moscow office of F5 Networks' NGINX, ZDNet reports »

On Thursday, police…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPPI

Spectrum

$8.89

0.21 (2.42%)

10:35
12/13/19
12/13
10:35
12/13/19
10:35
Options
Spectrum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$133.61

33.22 (33.09%)

10:34
12/13/19
12/13
10:34
12/13/19
10:34
On The Fly
Sarepta jumps as analysts react to 'surprise' FDA reversal on Vyondys53 »

Shares of Sarepta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$17.02

(0.00%)

10:32
12/13/19
12/13
10:32
12/13/19
10:32
Hot Stocks
Gap's Old Navy unit teams up with Postmates for on-demand gift delivery »

Gap's Old Navy unit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
12/13/19
12/13
10:30
12/13/19
10:30
General news
Treasury Action: yields remain lower, led by the front end, amid a lack of clarity »

Treasury Action: yields…

10:30
12/13/19
12/13
10:30
12/13/19
10:30
General news
The October U.S. business inventory report tracked estimates »

The October U.S. business…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$317.78

0.64 (0.20%)

10:29
12/13/19
12/13
10:29
12/13/19
10:29
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says Phase Two…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$317.78

0.64 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$318.00

0.86 (0.27%)

10:29
12/13/19
12/13
10:29
12/13/19
10:29
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says 25% tariffs on…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$318.00

0.86 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$318.23

1.09 (0.34%)

10:27
12/13/19
12/13
10:27
12/13/19
10:27
General news
Trump says Dec. 15 tariffs will not be charged due to phase one deal »

President Trump just…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$318.23

1.09 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.